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Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma)
were continuously exposed to increasing concentrations of the murine double minute 2 inhibitor nutlin-3, resulting in the
emergence of nutlin-3-resistant, p53-mutated sublines displaying a multi-drug resistance phenotype. Only 2 out of 28 sublines
adaptedtovariouscytotoxicdrugsharbouredp53mutations.Nutlin-3-adaptedUKF-NB-3cells(UKF-NB-3
rNutlin
10lM,harbouring
a G245C mutation) were also radiation resistant. Analysis of UKF-NB-3 and UKF-NB-3
rNutlin
10lM cells by RNA interference
experimentsandlentiviraltransduction ofwild-typep53intop53-mutatedUKF-NB-3
rNutlin
10lMcellsrevealedthatthelossofp53
function contributes to the multi-drug resistance of UKF-NB-3
rNutlin
10lM cells. Bioinformatics PANTHER pathway analysis
basedonmicroarraymeasurementsofmRNAabundanceindicatedasubstantialoverlapinthe signallingpathwaysdifferentially
regulated between UKF-NB-3
rNutlin
10lM and UKF-NB-3 and between UKF-NB-3 and its cisplatin-, doxorubicin-, or vincristine-
resistant sublines. Repeated nutlin-3 adaptation of neuroblastoma cells resulted in sublines harbouring various p53 mutations
with high frequency. A p53 wild-type single cell-derived UKF-NB-3 clone was adapted to nutlin-3 in independent experiments.
Eight out of ten resulting sublines were p53-mutated harbouring six different p53 mutations. This indicates that nutlin-3 induces
de novo p53 mutations not initially present in the original cell population. Therefore, nutlin-3-treated cancer patients should be
carefully monitored for the emergence of p53-mutated, multi-drug-resistant cells.
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The tumour suppressor protein p53 is the so-called guardian
of the genome that is activated in response to (genotoxic)
stress, resulting in cell cycle inhibition and DNA repair or cell
death. Many anti-cancer drugs are suspected to induce their
anti-cancer effects, at least in part, through induction of p53.
The important role of p53 as tumour suppressor is illustrated
by the fact that TP53, the gene encoding for p53, is the most
frequently mutated gene in cancer cells. About 50% of all
tumours are characterised by cancer cells in which p53
function is damaged through expression of mutated proteins
or loss of expression. Moreover, in many cell lines harbouring
wild-type p53, p53 response is impaired due to changes in its
up- and/or downstream signalling pathways.
1
Currently, numerous cancer treatment approaches are
dedicated to the activation of p53 in p53 wild-type cancer
cells.
1 One approach is to interfere with the interaction of p53
and its regulator murine double minute 2 (MDM2, in humans
also called HDM2). When p53 is activated, it transcriptionally
induces MDM2 expression via binding to the P2 promoter of
the MDM2 gene. MDM2 physically interacts with p53, thereby
inhibiting its transactivation function, mediating p53 export
from the nucleus, and inducing proteasomal degradation
of p53.
1,2
Nutlin-3 is a prototype, small-molecule MDM2 inhibitor
and non-genotoxic activator of p53.
1,2 Initially, it was hoped
that the so-called non-genotoxic p53 activators, such as
nutlin-3, that do not target the DNA integrity and exert less
nonspeciﬁc toxicity than the traditional cytotoxic drugs may
cause less genomic instability and result in reduced formation
of resistant cells. This hope was challenged by some recent
ﬁndings. Nutlin-3 was shownto induce DNA damage probably
by MDM2 inhibition-dependent and -independent mechanisms.
3,4
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www.nature.com/cddisMoreover, nutlin-3 treatment of U2OS osteosarcoma cells
and HCT116 colon cancer cells resulted in the emergence of
tetraploid, nutlin-3-resistant cells. In nutlin-3-treated SJSA-1
osteosarcoma cells, p53-mutated cells emerged.
5,6
Here, we investigated the nutlin-3-induced resistance
formation in a panel of neuroblastoma, rhabdomyosarcoma,
and melanoma cells. Nutlin-3 had already been shown
to exert anti-cancer effects in neuroblastoma, rhabdomyo-
sarcoma, and melanoma cells.
7–12 All of these entities are
characterised by relatively low frequencies of p53 muta-
tion,
8,13–16 making them possible candidates for nutlin-3
treatment. Our results show that nutlin-3-adaptation results
with high frequency in the acquisition of p53 mutations in
originallyp53wild-typecells.Ingeneral,p53-mutatednutlin-3-
resistant cells display a multi-drug-resistant phenotype.
Transcriptomics and subsequent bioinformatics pathway
analysis suggested an overlap in the resistance-associated
pathways in cells adapted to nutlin-3 and those adapted to
cytotoxic anti-cancer drugs. Results from the adaptation of a
single wild-type p53 cell-derived clone of the neuroblastoma
cell line UKF-NB-3 indicate that nutlin-3 induces de novo p53
mutations.
Results
Continuous exposure of p53 wild-type neuroblastoma,
rhabdomyosarcoma, and melanoma cell lines to nutlin-3
results in the establishment of p53-mutated, multi-drug-
resistant sublines. Continuous exposure to increasing
nutlin-3 concentrations for 6–13 passages (Supplementary
Table 1) of the neuroblastoma cell lines UKF-NB-3, UKF-NB-2,
and UKF-NB-6, the rhabdomyosarcoma cell line UKF-Rhb-1,
and the melanoma cell lines Colo-679 and Mel-HO resulted in
the formation of p53-mutated sublines (UKF-NB-3
rNutlin
10mM:
G245C (homozygote); UKF-NB-2
rNutlin
10mM: G117W (hetero-
zygote); UKF-NB-6
rNutlin
10mM: K132N (heterozygote), P223L
(homozygote); UKF-Rhb-1
rNutlin
10mM: D281N (homozygote);
Colo-679
rNutlin
20mM: C238F (heterozygote); Mel-HO
rNutlin
20mM:
R248Q (heterozygote)). The p53 mutations became detectable
in UKF-NB-3
rNutlin
10mM cells after ﬁve passages in the
presence of nutlin-3, in UKF-Rhb-1
rNutlin
10 cells after four
passages, in Colo-679
rNutlin
20mM cells after four passages,
and in Mel-HO
rNutlin
20mM cells after three passages.
In general, the nutlin-3-adapted cell lines showed decreased
sensitivitytovariousanti-cancerdrugs(Table1;Supplementary
Table 2).
Repeated adaptation of UKF-NB-3 and UKF-NB-6 cell
lines to nutlin-3. To investigate whether the adaptation of
cancer cells to nutlin-3 and the accompanying emergence
of p53 mutations are reproducible, 9 additional nutlin-3-
resistant UKF-NB-3 sublines and 10 additional nutlin-3-
resistant UKF-NB-6 cell sublines were established
(Table 2). Adaptation times ranged from 8 to 14 passages,
indicating repeatability of the process in both the cell lines
(Supplementary Table 1). Out of the nine nutlin-3-resistant
UKF-NB-3 sublines, four harboured p53 mutations (three
times D281G, one time P278A, Table 2). All 10 additional
nutlin-3-resistant UKF-NB-6 sublines harboured various p53
mutations (Table 2).
Repeated adaptation of a single p53 wild-type cell-
derived UKF-NB-3 clone to nutlin-3 results in sublines
harbouring varying p53 mutations. The emergence of
p53-mutated cells during nutlin-3 adaptation may be the
consequence of the selection of a preexisting p53-mutated
sub-population or nutlin-3 may favour the formation of novel
p53 mutations in p53 wild-type cells. A total of 10 single cell
clones of UKF-NB-3 were established and all were found to
be p53 wild-type. Next, one single p53 wild-type cell-derived
UKF-NB-3 clone was adapted to growth in the presence
of nutlin-3 in 10 independent experiments. A total of 7–11
passages were needed for nutlin-3 adaptation (Supplemen-
tary Table 3). Eight of the resulting ten sublines harboured
six different p53 mutations (Table 3).
P53 status in cytotoxic drug-adapted cell lines. A
number of sublines of the investigated cell lines adapted
to different cytotoxic drugs were analysed for their p53
status. Among UKF-NB-3 sublines adapted to 11 different
cytotoxic drugs (UKF-NB-3
rCDDP
1000 cisplatin (CDDP);
Table 1 Sensitivity of UKF-NB-3 and UKF-NB-3
rNutlin
10mM cells to a panel of established cytotoxic drugs indicated by the concentration that reduces cell viability
by 50% (IC50
a) indicated by MTT assay after a 5-day treatment period
IC50 (ng/ml
a)
UKF-NB-3
rNutlin
10lM
Drug UKF-NB-3
After 7 passages of
adaptation to nutlin-3
After 20 passages of
adaptation to nutlin-3
After 7 passages of adaptation to
nutlin-3 plus 20 passages cultivation
in the absence of nutlin-3
Nutlin-3
a 1.01±0.11 35.09±4.21 38.71±5.60 34.88±6.75
Vincristine 0.29±0.04 1.41±0.33 1.32±0.26 1.36±0.20
Cisplatin 108.77±22.32 293.02±31.63 342.52±42.71 280.14±24.83
Actinomycin D 0.20±0.05 0.59±0.18 0.70±0.24 0.61±0.18
Melphalan 178.69±52.47 439.56±46.71 451.02±51.31 426.22±44.89
Paclitaxel 1.33±0.31 3.48±0.42 3.25±0.18 3.09±0.41
Doxorubicin 9.18±1.64 24.21±4.03 28.41±3.97 29.97±5.86
Topotecan 0.90±0.06 3.95±1.09 4.22±0.85 3.77±0.68
aAll concentrations are expressed in ng/ml, except nutlin-3 concentrations that are expressed in mM
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2
Cell Death and DiseaseUKF-NB-3
rDAC
8 dacarbazine (DAC); UKF-NB-3
rDOX
20
doxorubicin (DOX); UKF-NB-3
rGEMCI
10 gemcitabine (GEMCI);
UKF-NB-3
rIRINO
800 irinotecan (IRINO); UKF-NB-3
rMEL
1000
melphalan (MEL); UKF-NB-3
rOXALI
2000 oxaliplatin (OXALI);
UKF-NB-3
rPCL
20 paclitaxel (PCL); UKF-NB-3
rTOPO
15 topo-
tecan (TOPO); UKF-NB-3
rVCR
10 vincristine (VCR); and
UKF-NB-3
rVINOR
20 vinorelbine (VINOR); Supplementary
Table 4), only UKF-NB-3
rVCR
10 showed a p53 mutation
(C135F, heterozygote) that was different from the G245C
mutation observed in UKF-NB-3
rNutlin
10mM cells. Among the
eight UKF-Rhb-1 sublines adapted to anti-cancer drugs
(UKF-Rhb-1
rCDDP
1000 CDDP; UKF-Rhb-1
rDOCE
10 docetaxel
(DOCE); UKF-Rhb-1
rDOX
10 DOX; UKF-Rhb-1
rGEMCI
10
GEMCI; UKF-Rhb-1
rIRINO
200 IRINO; UKF-Rhb-1
rMEL
400
MEL; UKF-Rhb-1
rOXALI
1000 OXALI; and UKF-Rhb-1
rVCR
10
VCR; Supplementary Table 4), only the UKF-Rhb-1
rVCR
10
subline harboured a p53 mutation (K291X, heterozygote)
that differed from the D281N mutation detected in UKF-
Rhb-1
rNutlin
10mM cells. No p53 mutations were found in
the UKF-NB-2 (UKF-NB-2
rCDDP
1000, UKF-NB-2
rDOX
20, and
UKF-NB-2
rVCR
10) or melanoma sublines (Colo-679
rVCR
20,
Colo-679
rPLX4032
10mM, MelHO
rVCR
10, MelHO
rCDDP
1000,
MelHO
rDAC
20, and MelHO
rPLX4032
10mM; Supplementary
Table 4). These data do not suggest the acquisition of p53
mutations to be a common event in these cell lines.
Sensitivity of UKF-NB-3
rNutlin
10lM cells to cytotoxic
drugs and radiation. In order to further characterise the
resistance phenotype induced by adaptation to nutlin-3, the
UKF-NB-3
rNutlin
10mM cells were investigated in more detail.
In addition to their decreased sensitivity to a broad panel of
different anti-cancer drugs (Table 1), UKF-NB-3
rNutlin
10mM
cells showed a strongly reduced sensitivity to irradiation
(Figure 1). Among the investigated cell lines, the
chemoresistant UKF-NB-3 sublines (UKF-NB-3
rNutlin
10mM,
UKF-NB-3
rVCR
10,U K F - N B - 3
rDOX
20, and UKF-NB-3
rCDDP
1000)
generally showed a decreased sensitivity to irradiation
compared with the parental UKF-NB-3 cells.
Investigation of caspase 3/7 activation in response to
cytotoxic drugs revealed that apoptosis induction is reduced
and delayed in UKF-NB-3
rNutlin
10mM cells compared with
UKF-NB-3 (Figure 2).
Table 2 p53 status of UKF-NB-3 and UKF-NB-6 sublines adapted to nutlin-3 in independent experiments
UKF-NB-3 sublines p53 status UKF-NB-6 sublines p53 status
UKF-NB-3
rNutlin
10mM G245C
a,b UKF-NB-6
rNutlin
10mM K132N
c, P223L
b
UKF-NB-3
rNutlin
10mM I Wild type UKF-NB-6
rNutlin
10mM I S241F
b
UKF-NB-3
rNutlin
10mM II Wild type UKF-NB-6
rNutlin
10mM II C277F
b
UKF-NB-3
rNutlin
10mM III Wild type UKF-NB-6
rNutlin
10mM III C277F
b
UKF-NB-3
rNutlin
10mM IV Wild type UKF-NB-6
rNutlin
10mM IV C135F
c, D281Y
c
UKF-NB-3
rNutlin
10mM V Wild type UKF-NB-6
rNutlin
10mM V C277F
b
UKF-NB-3
rNutlin
10mM VI P278A
c UKF-NB-6
rNutlin
10mM VI R248Q
c
UKF-NB-3
rNutlin
10mM VII D281G
c UKF-NB-6
rNutlin
10mM VII C277F
b
UKF-NB-3
rNutlin
10mM VIII D281G
c UKF-NB-6
rNutlin
10mM VIII C277F
b
UKF-NB-3
rNutlin
10mM IX D281G
c UKF-NB-6
rNutlin
10mM IX C277F
b
UKF-NB-6
rNutlin
10mM X R248Q
b
aType of p53 mutation
bHomozygote
cHeterozygote
Table 3 p53 status in nutlin-3-adapted sublines of the p53 wild-type UKF-NB-3
clone 2
Subline p53 status
UKF-NB-3clone2
rNutlin
10mMI Wild type
UKF-NB-3clone2
rNutlin
10mMII Wild type
UKF-NB-3clone2
rNutlin
10mMIII H168R (heterozygote)
UKF-NB-3clone2
rNutlin
10mMIV H168R (heterozygote)
UKF-NB-3clone2
rNutlin
10mMV C277F (heterozygote)
UKF-NB-3clone2
rNutlin
10mMVI H168R (heterozygote),
G245S (homozygote)
UKF-NB-3clone2
rNutlin
10mMVII F270L (heterozygote)
UKF-NB-3clone2
rNutlin
10mMVIII H168R (heterozygote)
UKF-NB-3clone2
rNutlin
10mMIX R280S (heterozygote),
D281G (heterozygote)
UKF-NB-3clone2
rNutlin
10mMX N239D (heterozygote)
1Gy 3Gy
* *
* *
*
60
80
100
120
20
0
40
60
80
100
120
20
0
40
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
5 Gy 8 Gy
* * * * *
100
120
20
0
40
60
80
100
120
20
0
40
60
80 * *
**
*
Figure 1 Radiation sensitivity of the UKF-NB-3 cell line, its sublines resistant to
nutlin-3 (UKF-NB-3
rNutlin
10mM), VCR (UKF-NB-3
rVCR
10), CDDP (UKF-NB-
3
rCDDP
1000), or DOX (UKF-NB-3
rDOX
20), and UKF-NB-3 cells transfected with
lentiviral vectors expressing shRNA directed against p53 (UKF-NB-3
p53 shRNA)o r
scrambled shRNA (UKF-NB-3
scr shRNA). A total of 1 10
4 cells were seeded per
well in 96-well plates, allowed to adhere for about 5h, irradiated, and viability was
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
24h post irradiation. *Po0.05 relative to UKF-NB-3
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3
Cell Death and DiseasePrevious investigations had shown that transient treatment
of osteosarcoma cells and colorectal cancer cells with nutlin-3
may result in the formation of tetraploid clones. Tetraploid
clonesofHCT116showeddecreasedsensitivitytoCDDPand
g-irradiation.
5 However, in nutlin-3-treated UKF-NB-3 neuro-
blastoma cells, no formation of tetraploid cells was detected,
whereas nutlin-3 treatment of SJSA sarcoma cells resulted in
detectable tetraploidy (Supplementary Figure 1). In contrast,
treatment of UKF-NB-3 cells with the aurora kinase inhibitor
VX680 (tozasertib), a positive control known to induce
tetraploidy, resulted in the formation of tetraploid cells.
Role of p53 mutation in UKF-NB-3
rNutlin
10lM cell chemo-
and radiation resistance. In concordance with its action
on MDM2, nutlin-3 was shown to be speciﬁcally cytotoxic
to p53 wild-type neuroblastoma and rhabdomyosarcoma
cells.
7,11.P53 mutations may not only be associated with a
loss of function but also with a gain of oncogenic functions,
increasing tumour aggressiveness and metastatic potential,
as well as drug resistance.
17 Therefore, the role of the
G245C mutation in UKF-NB-3
rNutlin
10mM cells was further
elucidated in the context of their sensitivity/resistance to anti-
cancer drugs. Nutlin-3 or CDDP induced expression of the
p53 target genes CDKN1A (encoding for p21), PMAIP1
(encoding for NOXA), MDM2, and GADD45 in p53 wild-type
UKF-NB-3 cells but not in UKF-NB-3
rNutlin
10mM cells
(Supplementary Figure 2A), indicating that p53 lost its
function as transcription factor in UKF-NB-3
rNutlin
10mM
cells. Accordingly, chromatin immunoprecipitation experi-
ments revealed a lack of p53 binding to the promoters of
p21, PMAIP1, or GADD45 promoters in UKF-NB-3
rNutlin
10mM
cells (Supplementary Figure 2B).
Next, p53 expression was suppressed in UKF-NB-3
rNu-
tlin
10mM cells using a lentiviral vector expressing p53 shRNA,
resulting in the subline UKF-NB-3
rNutlin
10mMp53-shRNA (see
Rothweiler et al;
18 Supplementary Figure 3). The chemosen-
sitivity proﬁle of UKF-NB-3
rNutlin
10mMp53-shRNA cells did not
differ from that of UKF-NB-3
rNutlin
10mM cells (Supplementary
Table 5), suggesting that the G245C mutation does not result
in a gain of function of p53 in the context of cancer cell
chemoresistance in this cell system.
UKF-NB-3 cells transduced with a lentiviral vector expres-
singp53shRNA(UKF-NB-3
p53-shRNA,Rothweileretal
18)were
used to investigate the inﬂuence of loss of p53-function on
chemosensitivity of UKF-NB-3 cells. UKF-NB-3
p53-shRNA cells
showed a decreased sensitivity to a range of different anti-
cancer drugs (Supplementary Table 2) in comparison with
UKF-NB-3 cells and UKF-NB-3
scr-shRNA cells (control trans-
duced with a vector expressing scrambled shRNA). This
indicates that loss of p53 function is associated with
decreased sensitivity of UKF-NB-3 cells to cytotoxic therapy.
Moreover, p53 appears to have a dominant role in the
response of UKF-NB-3 cells to irradiation. Although all
investigated chemoresistant UKF-NB-3 cell lines were less
sensitive to irradiation than the parental UKF-NB-3 cells,
resistancewasmorepronouncedinthep53-mutatedcelllines
(UKF-NB-3
rNutlin
10mM and UKF-NB-3
rVCR
10) than in the p53
wild-type cells (UKF-NB-3
rDOX
20 and UKF-NB-3
rCDDP
1000).
In addition, UKF-NB-3
p53-shRNA cells were similar irradiation
resistant like the p53-mutated cell lines UKF-NB-3
rNutlin
10mM
and UKF-NB-3
rVCR
10 (Figure 1).
Finally, UKF-NB-3
rNutlin
10mM cells were transduced with a
lentiviral vector encoding for wild-type p53 (UKF-NB-3
rNu-
tlin
10mMwtp53 Supplementary Figure 4). UKF-NB-3
rNu-
tlin
10mMwtp53 cells showed increased sensitivity to nutlin-3
andcytotoxic drugs(Table4),aswellastoradiation(Figure3)
compared with UKF-NB-3
rNutlin
10mM cells or UKF-NB-3
rNu-
tlin
10mM cells transduced with a control vector. However, their
sensitivity to nutlin-3 was still reduced when compared with
that of the parental UKF-NB-3 cells.
UKF-NB-3
rNutlin
10lM cells remain resistant against
multiple drugs after long-time cultivation in the absence
of nutlin-3. Previous reports had suggested that treatment
of different cancer cell lines with cytotoxic drugs may lead to
UKF-NB-3
vincristine
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Figure 2 Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3
rNutlin
10mM cells
treated nutlin-3 (10mM), VCR (10ng/ml), DOX (20ng/ml), or CDDP (1000ng/ml).
*Po0.05 relative to non-treated control
Table 4 Sensitivity of UKF-NB-3 cells, UKF-NB-3
rNutlin
10mM cells, and UKF-NB-3
rNutlin
10mM cells transduced with a lentiviral vector encoding wild-type p53
(UKF-NB-3
rNutlin
10mMwtp53), UKF-NB-3
rNutlin
10mM cells transduced with a control vector (UKF-NB-3
rNutlin
10mMcontrol) to nutlin-3 or established cytotoxic drugs
indicated by the concentration that reduces cell viability by 50% (IC50
1 ) indicated by MTT assay after a 5-day treatment period
Cell line Nutlin-3
a Vincristine Paclitaxel Topotecan
UKF-NB-3 0.95±0.16 0.20±0.02 0.92±0.26 0.90±0.08
UKF-NB-3
rNutlin
10mM 39.12±2.82 1.29±0.13 2.98±0.70 3.30±0.14
UKF-NB-3
rNutlin
10mMwtp53 3.31±0.28 0.48±0.04 1.62±0.11 1.23±0.14
UKF-NB-3
rNutlin
10mMcontrol 41.52±10.18 1.34±0.18 2.95±0.63 3.47±0.46
aAll concentrations are expressed in ng/ml, except nutlin-3 concentrations that are expressed in mM
Nutlin-3 induces de novo p53 mutations
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Cell Death and Diseasea selection of drug-resistant cancer cells.
20,21 After withdrawal
of cytotoxic drugs, these cell lines returned to their chemo-
sensitive phenotype. However, UKF-NB-3
rNutlin
10mM cells
retained their chemoresistance phenotype after 20 passages
in the absence of nutlin-3 (Table 1), indicating that adaptation
to nutlin-3 does not cause the reversible enrichment of a
p53-mutated cancer cell fraction.
Transcriptomics analysis of gene expression in UKF-
NB-3
rNutlin
10lM cells. In order to get an idea of the number
of changes that result from the adaptation of UKF-NB-3
cells to nutlin-3 at the transcriptome level, we compared
gene expression at the mRNA level between the parental
UKF-NB-3 cell line and its sublines UKF-NB-3
rNutlin
10mM,
UKF-NB-3
rVCR
10 UKF-NB-3
rCDDP
1000, and UKF-NB-3
rDOX
20
by gene microarray analysis (Supplementary Table 6).
The number of signiﬁcantly differentially expressed genes
(false discovery rate (FDR) o0.05, corrected for multiple
testing) varied between 3657 (UKF-NB-3 versus UKF-NB-
3
rNutlin
10mM) and 6375 (UKF-NB-3 versus UKF-NB-
3
rCDDP
1000) being less than a twofold difference. The
expression of 465 genes was signiﬁcantly differentially
regulated in the same direction (i.e., up or down) between
UKF-NB-3 and each drug-adapted subline (Supplementary
Table 6). Comparison of the number of genes that were
signiﬁcantly differentially regulated in the same direction in
three resistant sublines relative to UKF-NB-3 revealed the
highest overlap in the three cell lines adapted to the
established cytotoxic drugs VCR, CDDP, and DOX (1571
genes), whereas the overlaps between UKF-NB-3
rNutlin
10mM
cells and the other cell lines resulted in lower consistencies
(596–790 genes; Supplementary Table 6). Similar results
were obtained for the overlaps of genes signiﬁcantly
differentially regulated in the same direction in two resistant
sublines compared with UKF-NB-3 (Supplementary Table 6).
Bioinformatics pathway analysis using the PANTHER
database revealed that expression of genes from 8 (UKF-
NB-3 versus UKF-NB-3
rNutlin
10mM) to 18 (UKF-NB-3 versus
UKF-NB-3
rVCR
10) signal transduction pathways signiﬁcantly
differed (P o0.05, corrected for multiple testing) between the
UKF-NB-3 cell line and the drug-adapted sublines (Supple-
mentary Table 7). The three most signiﬁcantly affected
signalling pathways between UKF-NB-3 and UKF-NB-3
rNu-
tlin
10mM cells were ‘p53 pathway feedback loops 2’, ‘Wnt
signalling’, and ‘p53 pathway’. Notably, the overall overlap
was very high, with seven of the eight pathways signiﬁcantly
differentially regulated between UKF-NB-3 and UKF-NB-
3
rNutlin
10mM cells were also found to be signiﬁcantly differen-
tially regulated between UKF-NB-3 cells and UKF-NB-
3
rCDDP
1000, UKF-NB-3
rVCR
10, or UKF-NB-3
rDOX
20 cells
(Supplementary Table 7).
Discussion
Nutlin-3 inhibits the physical interaction between p53 and
its inhibitor MDM2, and activates p53 responses in p53 wild-
type cancer cells.
1,2 Neuroblastomas, rhabdomyosarcomas,
and melanomas are known to be rarely p53 mutated,
8,13–16
and therefore considered as promising candidates for
p53-activating agents. In this report, continuous exposure of
p53 wild-type cells from a panel of neuroblastoma, rhabdo-
myosarcoma, and melanoma cell lines to increasing nutlin-3
concentrations led to the emergence of nutlin-3-resistant
sublines within total 28 out of 35 nutlin-3-adapted sublines
harbouring p53 mutations. Investigation of 28 cytotoxic drug-
adapted sublines of the investigated cell lines revealed only
two p53-mutated cell lines (UKF-NB-3
rVCR
10 and UKF-Rhb-
1
rVCR
10). This indicates that induction of p53 mutation is a
rare event during chemoresistance acquisition in these cell
lines.
All of the p53 mutations detected in nutlin-3-adapted cells
are missense mutations in the DNA binding domain of p53.
Thus, they represent the same type of p53 aberration that is
most commonly found in tumour samples and cancer cell
lines. Indeed, all but one (G117W) of the mutations of p53 that
we report here to be generated upon nutlin-3 adaptation have
been previously found in patient biopsies and established
cancer cell lines (see http://www-p53.iarc.fr/), conﬁrming that
the continuous treatment with nutlin-3 confers a strong
selection pressure against functional wild-type p53. Interest-
ingly, however, although we ﬁnd mutations affecting the
so-called hotspot codons (i.e., example G245 and R248) – these
are among the p53 residues most frequently found mutated in
tumours – we have also detected ‘rare’ mutations that have
been reported in only a very small number of tumour samples
andcelllines(i.e.,P223L,S241F,andR280S).Theproperties
of such mutated p53 proteins are not well characterised.
However, given that the residues affected lye within the DNA-
binding domain of p53, it seems likely that these mutations
also impair the transactivation function of the tumour
suppressor protein.
The nutlin-3-adapted p53-mutated cell lines UKF-NB-
3
rNutlin
10mM, UKF-NB-2
rNutlin
10mM, UKF-NB-6
rNutlin
10mM,
UKF-Rhb-1
rNutlin
10mM, Colo-679
rNutlin
20mM, and Mel-HO
r
Nutlin
20mM displayed multi-drug resistance phenotypes, that is,
5Gy
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Figure 3 Radiation sensitivity of the UKF-NB-3 cell line, its sublines resistant to
nutlin-3 (UKF-NB-3
rNutlin
10mM), UKF-NB-3
rNutlin
10mM cells transduced with a
lentiviral vector expressing wild-type p53 (UKF-NB-3
rNutlin
10mMwtp53), or UKF-NB-
3
rNutlin
10mM cells transduced with control vector (UKF-NB-3
rNutlin
10mMcontrol).
A total of 1 10
4 cells were seeded per well in 96-well plates, allowed to adhere for
about 5h, irradiated (5Gy), and viability was determined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide assay 24h post irradiation. *Po0.05 relative
to UKF-NB-3
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than their parental counterparts. Particular in neuroblastomas,
loss of p53 function has been correlated to chemoresistance,
more aggressive disease, and poor prognosis.
14,16,21,22
UKF-NB-3
rNutlin
10mM, the nutlin-3-adapted subline of the
neuroblastoma cell line UKF-NB-3, was investigated more in
detail. UKF-NB-3
rNutlin
10mM cells harboured a G245C muta-
tion. UKF-NB-3
rNutlin
10mM cells showed also a profound
resistance to radiation. An analysis of UKF-NB-3, UKF-NB-
3
rNutlin
10mM, and a UKF-NB-3 subline in which p53 was
depleted due to transduction with a lentiviral vector encoding
p53 shRNA indicated that the loss of p53 function contributes
to the multi-drug-resistant phenotype observed in UKF-NB-
3
rNutlin
10mM cells. In addition, bioinformatics PANTHER
pathway analysis based on transcriptomics data derived from
mRNAdetectionusinggenemicroarrayrevealedasubstantial
overlap in the signalling pathways signiﬁcantly differentially
regulated (P o0.05 after correction for multiple testing)
between UKF-NB-3
rNutlin
10mM and UKF-NB-3 cells, as well
as between those signiﬁcantly differentially regulated be-
tween UKF-NB-3 and UKF-NB-3
rCDDP
1000, UKF-NB-
3
rDOX
20 and UKF-NB-3
rVCR
10 cells. CDDP concentrations
that were cytotoxic to UKF-NB-3
rNutlin
10mM cells did neither
induce expression of p53 target genes nor binding of p53 to
the promoters of selected target genes. Moreover, apoptosis
induction as indicated by caspase activation was reduced and
delayed in UKF-NB-3
rNutlin
10mM cells relative to UKF-NB-3
cells. As inhibition of p53 expression in UKF-NB-3
rNutlin
10mM
cells did not affect their sensitivity to the investigated anti-
cancer drugs, the G245C mutation appears to be a loss-of-
function mutation and not to be associated with the gain of
oncogenic functions in the context of chemoresistance in this
cell system.
The ability of mutant p53 forms to inactivate wild-type p53
may differ in dependence of the type of mutation and also in
dependence of the speciﬁc conditions.
23 G245C-mutated p53
harbouring UKF-NB-3
rNutlin
10mM cells were sensitised to
toxicity induced by nutlin-3, cytotoxic drugs, and radiation
by transduction with a lentiviral vector expressing wild-
type p53 (UKF-NB-3
rNutlin
10mMwtp53) However, UKF-NB-
3
rNutlin
10mMwtp53 cells remained less sensitive to nutlin-3,
cytotoxic drugs, or radiation than parental UKF-NB-3 cells. It
remains unclear to which extent these differences are caused
by a wild-type p53-inactivating function of G245C-mutated
p53and/orbyotherchangesacquiredduringtheadaptationof
UKF-NB-3 cells to nutlin-3.
The emergence of p53-mutated, drug-resistant cells under
nutlin-3 exposure raises the question where these cells
originate from. Cytotoxic drugs had already been shown to
exert a selection pressure on certain cancer cell lines,
resulting in the enrichment of a of drug-resistant cancer cell
fraction.
19,20 After removal of the cytotoxic drugs, these cell
lines returned to their original chemosensitive phenotype. As
UKF-NB-3
rNutlin
10mM cells retained their chemoresistant pheno-
type even after 20 passages of cultivation in the absence of
nutlin-3, nutlin-3 does not appear to reversibly enhance a certain
cellular fraction present in the parental UKF-NB-3 cell line.
Nevertheless, nutlin-3 treatment may still result in the
(irreversible) expansion of p53-mutated cell fractions already
present in the parental UKF-NB-3 cell line. In a previous
report, nutlin-3 treatment of SJSA-1 osteosarcoma cells was
shown to result in the emergence of p53-mutated cells.
6 The
authors used a different approach (pulsed nutlin-3 exposure)
and detected different p53 mutations in different experi-
ments.
6 These ﬁndings are in concordance with our results
from the repeated adaptation of UKF-NB-3 and UKF-NB-6
neuroblastoma cells to nutlin-3 that also showed that various
p53 mutations emerge. On the basis of the varying p53
mutations in nutlin-3-selected SJSA-1 cells and the fact that
they did not receive growing cell colonies under continuous
nutlin-3 exposure, they suggested that the p53 mutations are
likely to arise during nutlin-3 treatment.
6 However, this
interpretation might not be conclusive, as nutlin-3 was shown
to also inhibit the growth of cells without functional p53 by
mechanisms involving p73 and E2F1.
24,25 Moreover, cells
were adapted by continuous nutlin-3 exposure in our
experiments. Differences in the used cell lines may be
responsible for this discrepancy. The same group had also
previously shown that nutlin-3 treatment of U2OS osteo-
sarcoma and HCT116 colon carcinoma cells may promote
endoreduplication and emergence of nutlin-3-resistant tetra-
ploid cells.
5 In our experiments, we detected tetraploid
SJSA-1 cells but did not ﬁnd tetraploid UKF-NB-3 cells. This
supports the assumption that different cells and/or cell types
may clearly react differently to nutlin-3 treatment.
The emergence of various p53 mutations after repeated
adaptation of a cell line to nutlin-3 may also not be sufﬁcient to
conclude that nutlin-3 induces p53 mutations, as cancer cell
lines and tumours may harbour various p53 mutations.
26–28 In
order to investigate whether nutlin-3 induces p53 mutations or
selects p53-mutated cell populations that are already present
intheoriginalcellline,ap53wild-typesinglecell-derivedclone
of UKF-NB-3 was established and adapted to nutlin-3 in 10
independent experiments. Eight out of ten nutlin-3-adapted
sublines harboured six different p53 mutations, indicating
nutlin-3 to induce the emergence of novel p53 mutations that
were not present in the original cell population.
The mechanisms by which nutlin-3 favours p53 mutations
remain unclear. Nutlin-3 was shown to induce and/or promote
DNA damage.
3,4 Moreover, we show that the numbers of
genes signiﬁcantly differentially expressed (Po0.05 after
correction for multiple testing) between UKF-NB-3 and UKF-
NB-3
rNutlin
10mM (3657) do not too strongly differ from those
differentially expressed between UKF-NB-3 and the cytotoxic
drug-adapted cell lines UKF-NB-3
rCDDP
1000 (CDDP
adapted, 6375), UKF-NB-3
rDOX
20 (DOX adapted, 4711),
and UKF-NB-3
rVCR
10 (VCR adapted, 5885), especially
considering the fact that UKF-NB-3
rNutlin
10mM cells were only
cultivatedforafewpassagesinparallelwiththeparentalUKF-
NB-3 cells, whereas the establishment of the other cell lines
took more than a year. Therefore, nutlin-3 treatment does not
appear to induce much lesser changes to cancer cells than
less speciﬁc cytotoxic drugs. Moreover, more speciﬁc targeted
therapies appear to be in general associated with a relatively
rapid resistance development.
29,30 Consequently, interference
with DNA integrity and a speciﬁc selection pressure favouring
p53loss-of-functionmutationsmaybeinvolvedintheemergence
of p53-mutated cells under nutlin-3 exposure.
In conclusion, our results show that nutlin-3 treatment of a
panel of cell lines from three different entities (neuroblastoma,
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mutated and therefore considered as promising candidates
for nutlin-3 therapy reproducibly resulted in the irreversible
emergence of p53-mutated, multi-drug-resistant sublines. In
contrast to previous reports, nutlin-3 did not induce formation
of tetraploid cells. Induction of p53 mutation appears to be an
exclusive property of nutlin-3, as only 2 out of 28 neuroblas-
toma, rhabdomyosarcoma, and melanoma cell lines adapted
to various cytotoxic anti-cancer drugs developed p53 muta-
tions. Repeated adaptation of a single p53-wild type cell-
derived UKF-NB-3 clone in 10 independent experiments
resulted in eight sublines harbouring six different p53
mutations and two p53 non-mutated sublines, indicating that
nutlin-3 induces de novo p53 mutations and does not select
preexisting p53-mutated sub-populations already existent in
the original cell line. Although continuous nutlin-3 treatment
maynotcompletelyreﬂectthetumourexposuretonutlin-3ina
clinical setting, cancer patients treated with nutlin-3 (and
possibly also other MDM2 inhibitors or non-genotoxic p53
activators)shouldbecarefullymonitoredfortheemergenceof
p53-mutated, multi-drug-resistant cells.
Materials and Methods
Drugs. Nutlin-3 was purchased from Selleck Chemicals via BIOZOL GmbH
(Eching, Germany). VCR, CDDP, and PCL were obtained from TEVA GmbH
(Radebeul, Germany). DOX was received from Medac Gesellschaft fu ¨r klinische
Spezialpra ¨paratembH(Hamburg,Germany).MELandTOPOwerepurchasedfrom
GlaxoSmithKline GmbH and Co. KG (Munich, Germany). Actinomycin D was
received from MSD Sharp and Dome GmbH (Haar, Germany).
Cell lines. The N-myc-ampliﬁed neuroblastoma cell lines UKF-NB-2, UKF-NB-3,
and UKF-NB-6 were established from stage 4 neuroblastoma patients.
31–33 The
alveolar rhabdomyosarcoma cell line UKF-Rhb-1 was established from a bone
marrowmetastasis.
11ThemelanomacelllinesColo-679andMel-HOwereobtained
from the DSMZ (Braunschweig, Germany).
Parental chemosensitive cell lines were adapted to growth in the presence of
anti-cancer drugs by continuous exposure of these cell lines to the increasing
concentrations of these drugs as described before.
31,32
ThefollowingchemoresistantUKF-NB-3sublineswerederivedfromtheresistant
cancer cell line (RCCL) collection: UKF-NB-3
rCDDP
1000 (adapted to CDDP), UKF-
NB-3
rDAC
8 (DAC), UKF-NB-3
rDOX
20 (DOX), UKF-NB-3
rGEMCI
10 (GEMCI), UKF-
NB-3
rIRINO
800 (IRINO), UKF-NB-3
rMEL
400 (MEL), UKF-NB-3
rOXALI
2000 (OXALI),
UKF-NB-3
rPCL
20 (PCL), UKF-NB-3
rTOPO
15 (TOPO), UKF-NB-3
rVCR
10 (VCR),
and UKF-NB-3
rVINOR
20 (VINOR).
The following chemoresistant UKF-NB-2 sublines were derived from the RCCL
collection: UKF-NB-2
rCDDP
1000, UKF-NB-2
rDOX
20, and UKF-NB-2
rVCR
10.
The following chemoresistant UKF-Rhb-1 sublines were derived from the RCCL
collection: UKF-Rhb-1
rCDDP
1000 and UKF-Rhb-1
rDOCE
10 (DOCE), UKF-Rhb-
1
rDOX
10, UKF-Rhb-1
rGEMCI
10, UKF-Rhb-1
rIRINO
200, UKF-Rhb-1
rMEL
400, UKF-
Rhb-1
rOXALI
1000, and UKF-Rhb-1
rVCR
10
Moreover, the following melanoma sub-lines were derived from the RCCL
collection: Colo-679
rVCR
20, Colo-679
rPLX4032
10mM (PLX4032, vemurafenib),
MelHO
rVCR
20, MelHO
rCDDP
1000, MelHO
rDAC
20, and MelHO
rPLX4032
10mM.
The corresponding IC50 values for the parental cells and their drug-resistant
sublines are provided in Supplementary Table 4.
All cells were propagated in IMDM supplemented with 10% FBS, 100IU/ml
penicillin and 100mg/ml streptomycin at 371C. Cells were routinely tested for
mycoplasma contamination and authenticated by short tandem repeat proﬁling.
Standard molecular cloning techniques were used to generate lentiviral vectors
based on Lentiviral Gene Ontology vector technology (see http://www.lentigo-
vectors.de), and cell transduction was performed as described before.
11,18,34
Viability assay. Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromidedye reductionassayafter120h ofincubation,modiﬁed
as described before.
11,18
Irradiation procedure. A total of 10
4 cells were irradiated at room
temperature in 96-well cell culture plates (Greiner, Bio-ONE GmbH,
Frickenhausen, Germany) with single doses of X-rays ranging from 1 to 10Gy
using a linear accelerator (SL 75/5, Elekta, Crawley, UK) with 6MeV photons/
100cm focus–surface distance with a dose rate of 4.0Gy/min. Sham-irradiated
cultureswerekeptatroomtemperatureintheX-raycontrolroom,whereastheother
samples were irradiated.
Caspase 3/7 activation. Caspase activation was measured using the
Caspase-Glo 3/7 Assays (Promega, Mannheim, Germany) following the
manufacturer’s instructions.
Mutation analysis of p53. TP53 gene sequencing on cDNAs was
performed using the following four pairs of primers: TP53 Ex2-3-f 5-GTGA
CACGCTTCCCTGGAT-3 and TP53 Ex2-3-r 5-TCATCTGGACCTGGGTCTTC-3;
TP53 Ex4-5-f 5-CCCTTCCCAGAAAACCTACC-3 and TP53 Ex4-5-r 5-CTCC
GTCATGTGCTGTGACT-3; TP53 EX6-7f 5-GTGCAGCTGTGGGTTGATT-3 and
TP53 Ex6-7r 5-GGTGGTACAGTCAGAGCCAAC-3; and TP53 Ex8-9-f 5-CCTCA
CCATCATCACACTGG-3 and TP53 Ex8-9-r 5-GTCTGGTCCTGAAGGGTGAA-3.
In addition, all cell lines were examined for TP53 mutations by sequence analysis
of genomic DNA as described previously.
35 PCR was performed as described
before.
35 Each amplicon was sequenced bidirectionally.
Real-time PCR. Total RNA was isolated from cell cultures using TRI reagent
(Sigma-Aldrich, Munich, Germany). Reverse transcription and real-time PCR were
performed as described before,
36 using TaqMan Gene Expression Assays (Applied
Biosystems, Darmstadt, Germany). The results are presented as fold change.
Transcriptomics. Triplicates of UKF-NB-3, UKF-NB-3
rNutlin
10mM, UKF-NB-
3
rVCR
10 UKF-NB-3
rDOX
20, and UKF-NB-3
rCDDP
1000 cells were analysed for
global cellular gene expression at the mRNA level using GeneChip HGU133 Plus
2.0 (Affymetrix, Santa Clara, CA, USA) by the Fraunhofer Institut fu ¨r Zelltherapie
und Immunologie (Leipzig, Germany). mRNA was isolated using the RNeasy kit
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
Expression data were processed using the R/bioconductor packages ‘gcrma’
and ‘limma’ (http://www.r-project.org/ and http://www.bioconductor.org/) in order to
detect differentially expressed genes (FDR).
37 The results were corrected for
multipletestingtocontroltheFDRusingtheapproachofBenjaminiandHochberg.
38
Hierarchical clustering analysis was performed, and heatmaps were visualised
using the R package (http://www.r-project.org).
Signal transduction pathway bioinformatics. Additional statistical
analysis to interpret signiﬁcant expression changes was focusing on a pathway
analysisusingthePANTHERdatabase(http://www.pantherdb.org),whichidentiﬁes
global patterns in expression.
39 For each expert-curated pathway in the database,
potential differential expression was determined by a binomial test,
40 with subse-
quent Bonferroni correction for multiple testing, using the PANTHER human gene
reference list matching our microarrays and lists of differentially expressed genes
that passed an multiple-testing corrected threshold of FDR o0.05.
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